![Paolo Tarantino: Delivering chemo via HER2- and Trop2-targeted Antibody-drug conjugates (ADCs) has reshaped the way we treat Metastatic breast cancer (MBC)](https://oncodaily.com/pub/uploads/2023/08/Paolo-Tarantino-Twitter-1280x893.jpeg)
Photo from Paolo Tarantino / Twitter
Aug 15, 2023, 09:15
Paolo Tarantino: Delivering chemo via HER2- and Trop2-targeted Antibody-drug conjugates (ADCs) has reshaped the way we treat Metastatic breast cancer (MBC)
Paolo Tarantino, MD, Clinical Research Fellow at Dana-Farber Cancer Institute, stated on Twitter:
“Delivering chemo via HER2- & Trop2-targeted Antibody-drug conjugates (ADCs) has reshaped the way we treat Metastatic breast cancer (MBC). Beyond these two targets lays a vast land of opportunity, encompassing additional targets & novel ADC structures. Our latest review, led by Ilana Schlam, just out on CROH.”
For the article click here
Source: Paolo Tarantino/Twitter
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023